Scientists argue on whether or not to recommend Homeopathy

Image
ANI Washington DC
Last Updated : Jul 15 2015 | 10:48 AM IST

Two researchers are debating over the recommendation of Homeopathic medicines as one favours its usage and the other has totally contradicted views.

Peter Fisher of the Royal London Hospital for Integrated Medicine claimed that of all the major forms of complementary medicine, homeopathy was the most misunderstood.

He questioned the methods used to review the evidence for homeopathy and argued that the fact that one homeopathic treatment for a condition was ineffective didn't mean that another was ineffective as well.

Fisher added that most overviews have had more favourable conclusions as well, including a Health Technology Assessment commissioned by the Swiss federal government which concluded that homeopathy is probably effective for upper respiratory tract infections and allergies and several meta analyses of homeopathy as a whole and for specific conditions have been positive.

He concludes that doctors should put aside bias based on the alleged implausibility of homeopathy as when integrated with standard care homeopathy is safe, popular with patients, improves clinical outcomes without increasing costs and reduces the use of potentially hazardous drugs, including antimicrobials.

Contradicting to his point, Edzard Ernst of the University of Exeter said that most independent systematic reviews of randomised controlled trials have failed to show that homeopathy was effective and reviews with positive conclusions usually have serious methodological flaws.

He also argued that homeopathy could harm if it replaced an effective therapy and adding that he knew of several deaths that had occurred in this unnecessary way.

Ernst concluded that the axioms of homeopathy were implausible as its benefits did not outweigh its risks and its costs and opportunity costs were considerable.

The debate is published in the journal BMJ.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 15 2015 | 10:40 AM IST

Next Story